share_log

Theriva Biologics | 10-Q: Q2 2024 Earnings Report

Theriva Biologics | 10-Q: Q2 2024 Earnings Report

Theriva Biologics | 10-Q：2024財年二季報
美股SEC公告 ·  2024/08/13 20:22

Moomoo AI 已提取核心訊息

Theriva Biologics reported a net loss of $8.3 million ($0.43 per share) for Q2 2024, compared to a $5.1 million loss ($0.34 per share) in Q2 2023. Revenue remained minimal while R&D expenses were $3.0 million and G&A expenses decreased to $1.5 million. The company recorded a $4.0 million goodwill impairment charge during the quarter.The company's lead candidate VCN-01 continues to advance in clinical trials, with patient enrollment ongoing in the Phase 2 VIRAGE trial for pancreatic cancer. Positive topline data was reported from a Phase 1 trial of intravitreal VCN-01 in retinoblastoma patients. The FDA granted Fast Track Designation for VCN-01 in combination with chemotherapy for pancreatic cancer.With cash and equivalents of $16.6 million as of June 30, 2024, management expects current funding to support operations into Q2 2025. However, the company will require additional capital to advance later-stage clinical trials and commercialization efforts. During Q2, Theriva raised $1.8 million through an at-the-market offering of 4.4 million shares.
Theriva Biologics reported a net loss of $8.3 million ($0.43 per share) for Q2 2024, compared to a $5.1 million loss ($0.34 per share) in Q2 2023. Revenue remained minimal while R&D expenses were $3.0 million and G&A expenses decreased to $1.5 million. The company recorded a $4.0 million goodwill impairment charge during the quarter.The company's lead candidate VCN-01 continues to advance in clinical trials, with patient enrollment ongoing in the Phase 2 VIRAGE trial for pancreatic cancer. Positive topline data was reported from a Phase 1 trial of intravitreal VCN-01 in retinoblastoma patients. The FDA granted Fast Track Designation for VCN-01 in combination with chemotherapy for pancreatic cancer.With cash and equivalents of $16.6 million as of June 30, 2024, management expects current funding to support operations into Q2 2025. However, the company will require additional capital to advance later-stage clinical trials and commercialization efforts. During Q2, Theriva raised $1.8 million through an at-the-market offering of 4.4 million shares.
Theriva生物製品報告2024年第二季度淨虧損830萬美元（每股0.43美元），相比之下，2023年第二季度虧損510萬美元（每股0.34美元）。營業收入保持微不足道，而研發費用爲300萬美元，管理費用減少至150萬美元。公司在本季度記錄了400萬美元的商譽減值損失。公司主要候選藥物VCN-01繼續在臨牀試驗中推進，第二階段VIRAGE試驗的 pancreatic癌患者正在招募中。第一階段的視網膜母細胞瘤患者用VCN-01進行的玻璃體內注射試驗報告了積極的頂線數據。FDA已授予VCN-01與化療聯合用於胰腺癌的快速通道認證。截至2024年6月30日，公司現金及現金等價物爲1660萬美元，管理層預計當前資金可支持運營至2025年第二季度。然而，公司將需要額外資金以推進後期臨牀試驗和商業化工作。在第二季度，Theriva通過440萬股的市場發行籌集了180萬美元。
Theriva生物製品報告2024年第二季度淨虧損830萬美元（每股0.43美元），相比之下，2023年第二季度虧損510萬美元（每股0.34美元）。營業收入保持微不足道，而研發費用爲300萬美元，管理費用減少至150萬美元。公司在本季度記錄了400萬美元的商譽減值損失。公司主要候選藥物VCN-01繼續在臨牀試驗中推進，第二階段VIRAGE試驗的 pancreatic癌患者正在招募中。第一階段的視網膜母細胞瘤患者用VCN-01進行的玻璃體內注射試驗報告了積極的頂線數據。FDA已授予VCN-01與化療聯合用於胰腺癌的快速通道認證。截至2024年6月30日，公司現金及現金等價物爲1660萬美元，管理層預計當前資金可支持運營至2025年第二季度。然而，公司將需要額外資金以推進後期臨牀試驗和商業化工作。在第二季度，Theriva通過440萬股的市場發行籌集了180萬美元。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    2seventy bio
    TSVT
    -- 4.950
    Syros Pharmaceuticals
    SYRS
    -- 0.1360
    Dogwood Therapeutics
    DWTX
    -- 11.130
    Camp4 Therapeutics
    CAMP
    -- 5.490
    Anebulo Pharmaceuticals
    ANEB
    -- 1.390
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    科技巨頭財報季如火如荼，英偉達壓軸會表現如何？
    週四， $亞馬遜 (AMZN.US)$ 該公司報告第四季度調整後每股收益爲1.86美元，高於1.50美元的預期，營業收入爲1877.9亿美元，高於1873.2亿美元的預期。公司預測下一季度營收將低於華爾街的預期，預計本季度最多爲1550亿美元，而分析師們希望達到1580亿美元。 展开
    亞馬遜收益預覽：通過猜測開盤價格獲得獎勵！